UNICREDIT BANK/CALL/ASTRAZENECA/13500/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 03:47:06 2024-05-27 pm EDT | ||
| 0.63 EUR | 0.00% |
|
| Current month | +14.55% | ||
| 1 month | +14.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 0.63 | 0.00% |
| 24-05-24 | 0.63 | -1.56% |
| 24-05-23 | 0.64 | +3.23% |
| 24-05-22 | 0.62 | -3.13% |
| 24-05-21 | 0.64 | +23.08% |
Real-time BOERSE MUENCHEN
Last update May 27, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD4FHC |
| ISIN | DE000HD4FHC9 |
| Date issued | 2024-04-08 |
| Strike | 13,500 p |
| Maturity | 2024-12-18 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.71 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.14 € |
| Spread % | 20.29% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.53%
- Stock Market
- Warrants
- Warrant
